Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Nov 1;39(31):3506-3514.
doi: 10.1200/JCO.21.00703. Epub 2021 Jul 16.

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

Steven G DuBois  1 , M Meaghan Granger  2 , Susan Groshen  3 , Denice Tsao-Wei  3 , Lingyun Ji  3 , Anasheh Shamirian  4 , Scarlett Czarnecki  5 , Fariba Goodarzian  6 , Rachel Berkovich  6 , Hiroyuki Shimada  7 , Judith G Villablanca  4 , Kieuhoa T Vo  8 , Navin Pinto  9 , Yael P Mosse  10 , John M Maris  10 , Suzanne Shusterman  1 , Susan L Cohn  11 , Kelly C Goldsmith  12 , Brian Weiss  13 , Gregory A Yanik  14 , Clare J Twist  15 , Meredith S Irwin  16 , Daphne A Haas-Kogan  17 , Julie R Park  9 , Araz Marachelian  4 , Katherine K Matthay  8
Affiliations
Clinical Trial

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

Steven G DuBois et al. J Clin Oncol. .

Abstract

Purpose: 131I-metaiodobenzylguanidine (MIBG) is an active radiotherapeutic for neuroblastoma. The primary aim of this trial was to identify which of three MIBG regimens was likely associated with the highest true response rate.

Patients and methods: Patients 1-30 years were eligible if they had relapsed or refractory neuroblastoma, at least one MIBG-avid site, and adequate autologous stem cells. Patients received MIBG 18 mCi/kg on day 1 and autologous stem cell on day 15. Patients randomly assigned to arm A received only MIBG; patients randomly assigned to arm B received intravenous vincristine on day 0 and irinotecan daily on days 0-4; patients randomly assigned to arm C received vorinostat (180 mg/m2/dose) orally once daily on days 1 to 12. The primary end point was response after one course by New Approaches to Neuroblastoma Therapy criteria. The trial was designed with 105 patients to ensure an 80% chance that the arm with highest response rate was selected.

Results: One hundred fourteen patients were enrolled, with three ineligible and six unevaluable, leaving 105 eligible and evaluable patients (36 in arm A, 35 in arm B, and 34 in arm C; 55 boys; and median age 6.5 years). After one course, the response rates (partial response or better) on arms A, B, and C were 14% (95% CI, 5 to 30), 14% (5 to 31), and 32% (18 to 51). An additional five, five, and four patients met New Approaches to Neuroblastoma Therapy Minor Response criteria on arms A, B, and C, respectively. On arms A, B, and C, rates of any grade 3+ nonhematologic toxicity after first course were 19%, 49%, and 35%.

Conclusion: Vorinostat and MIBG is likely the arm with the highest true response rate, with manageable toxicity. Vincristine and irinotecan do not appear to improve the response rate to MIBG and are associated with increased toxicity.

Trial registration: ClinicalTrials.gov NCT02035137.

PubMed Disclaimer

Conflict of interest statement

Steven G. DuBoisConsulting or Advisory Role: BayerResearch Funding: Merck, Roche/Genentech, Lilly, Curis, Loxo, BMS, Eisai, Pfizer, Turning Point Therapeutics, Bayer, Salarius PharmaceuticalsTravel, Accommodations, Expenses: Roche/Genentech, Salarius PharmaceuticalsUncompensated Relationships: Ymabs Therapeutics Inc Susan GroshenEmployment: Pfizer Scarlett CzarneckiSpeakers' Bureau: United Therapeutics Yael P. MosseConsulting or Advisory Role: ASCO, Pfizer, Lilly, Auron Therapeutics, JumoResearch Funding: Pfizer John M. MarisStock and Other Ownership Interests: Tantigen BIO IncConsulting or Advisory Role: Auron Therapeutics, Illumina Radiopharmaceuticals, Jubilant DraxImagePatents, Royalties, Other Intellectual Property: GPC2 binders and CARs, Neuroblastoma antigens Suzanne ShustermanStock and Other Ownership Interests: Bristol Myers Squibb, GlaxoSmithKline, Intuitive Surgical, Kindred Biosciences, Merck, Nuvasive, OPKO Health, Regeneron, Surgalign, Amgen, BioTelemetry, RTI Surgical Holdings, EFOFEM biosciences, InVitae Susan L. CohnStock and Other Ownership Interests: Merck, Stryker, Amgen, Pfizer, AbbVie, Amgen, Lilly, Sanofi, Accelerated Medical Diagnostics, Novo Nordisk, Gilead Sciences, United Health Group, TevaHonoraria: Y-mAbs TherapeuticsResearch Funding: United Therapeutics, MerckOpen Payments Link: https://openpaymentsdata.cms.gov/physician/46569/summary Brian WeissResearch Funding: Novartis, Genentech, ExelixisTravel, Accommodations, Expenses: Exelixis, RocheOpen Payments Link: https://openpaymentsdata.cms.gov/physician/620363 Gregory A. YanikResearch Funding: Jazz Pharmaceuticals Meredith S. IrwinHonoraria: Bayer Daphne A. Haas-KoganConsulting or Advisory Role: Leidos Biomedical Research, SRA International, Gerson Lehrman Group, Guidepoint Global Araz MarachelianResearch Funding: Pfizer, United Therapeutics Katherine K. MatthayConsulting or Advisory Role: Resonance HealthNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
CONSORT diagram showing random assignment of 114 patients to yield 105 eligible and evaluable patients. MIBG, 131I-metaiodobenzylguanidine.
FIG 2.
FIG 2.
Waterfall plot according to randomized arm showing the sum of relative Curie score (Curie score after first course divided by baseline Curie score) minus 1 such that a value of 0 represents no change from baseline, a value of –1 represents a complete response by Curie score, and positive values represent increases in Curie score. A, B, and C correspond to arms A, B, and C. The heavy red line represents threshold for being considered to have had a partial response or better by Curie score.
FIG A1.
FIG A1.
PFS from time of random assignment for 105 patients according to randomized arm. PFS, progression-free survival.
FIG A2.
FIG A2.
OS from time of random assignment for 105 patients according to randomized arm. NA, not available; OS, overall survival.
See this image and copyright information in PMC

References

    1. Dubois SG, Geier E, Batra V, et al. : Evaluation of norepinephrine transporter expression and metaiodobenzylguanidine avidity in neuroblastoma: A report from the Children's Oncology Group. Int J Mol Imaging 2012:250834, 2012 - PMC - PubMed
    1. Glowniak JV, Kilty JE, Amara SG, et al. : Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 34:1140-1146, 1993 - PubMed
    1. Wilson JS, Gains JE, Moroz V, et al. : A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 50:801-815, 2014 - PubMed
    1. Kraal KC, Bleeker GM, van Eck-Smit BL, et al. : Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients. Eur J Cancer 76:188-196, 2017 - PubMed
    1. McCluskey AG, Boyd M, Ross SC, et al. : [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Clin Cancer Res 11:7929-7937, 2005 - PubMed

Publication types

MeSH terms

Associated data